Stock Market Today, Dec. 16: Pfizer Falls After Cutting 2025 Revenue Forecast
Summarize this article with:
By Emma Newbery – Dec 16, 2025 at 5:43PM ESTNYSE: PFEPfizerMarket Cap$150BToday's Changeangle-down(-3.40%) $0.90Current Price$25.53Price as of December 16, 2025 at 4:00 PM ETToday, Dec. 16, 2025, Pfizer's shrinking COVID cash flows could mean little growth next year as M&A bets will take time to deliver. ExpandNYSE: PFEPfizerToday's Change(-3.40%) $-0.90Current Price$25.53Key Data PointsMarket Cap$150BDay's Range$24.92 - $26.5052wk Range$20.91 - $27.69Volume112MAvg Vol68MGross Margin69.12%Dividend Yield6.51%Pfizer (PFE 3.40%), which develops and sells biopharmaceutical products worldwide, closed today's session (Dec. 16) at $25.53, down 3.41%. Trading volume reached 108.1 million shares, almost 60% above its three-month average.How the markets moved todayTuesday’s move followed Pfizer's announcement trimming 2025–2026 revenue expectations and highlighting faster COVID-19 erosion. Investors will watch to see whether new products and deals can restore earnings growth. The S&P 500 (^GSPC 0.24%) slipped 0.26% to 6,799, while the Nasdaq Composite (^IXIC +0.23%) added 0.23% to finish at 23,111. Pfizer’s commentary impacted its industry peers as well. Merck (MRK 2.00%) and Johnson & Johnson (JNJ 2.27%) fell 1.99% and 2.27%, respectively, as investors reassessed large pharma earnings power. What this means for investorsPfizer cut its 2025 revenue guidance from to $62 billion, down from between $61 billion and $64 billion. It reaffirmed its 2025 adjusted EPS of $3.00 - $3.15. It told investors it is expecting flat growth for 2026, with anticipated revenues between $59.5 billion and $62.5 billion. This is down to falling revenue from COVID drugs and expiring patents. The company said it is cutting costs and investing the proceeds into R&D. For example, it recently acquired a biopharmaceutical company focused on obesity and cardiometabolic diseases. It will push ahead with obesity drug trials in 2026. However, it could take time for newer initiatives to bear fruit. About the AuthorEmma Newberry is a contributing Motley Fool cryptocurrency analyst covering digital currencies and blockchain trends. She previously wrote for Motley Fool Money (formerly The Ascent) on personal finance, investing, retirement readiness, and crypto. Earlier in her career, Emma founded an English-language newspaper in Colombia and contributed to Olympic city bid campaigns. She holds a bachelor’s degree in English literature with creative writing from the University of East Anglia in the UK.TMFemmanewberyRead NextDec 13, 2025 •By Prosper Junior BakinyForget Teladoc and Buy This Healthcare Stock InsteadDec 12, 2025 •By Prosper Junior BakinyPfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026.Dec 9, 2025 •By Reuben Gregg BrewerDown 50%, Should You Buy the Dip on Pfizer?Dec 5, 2025 •By Prosper Junior Bakiny2 Headwinds Facing Pfizer Stock Going Into 2026Dec 2, 2025 •By Prosper Junior Bakiny2 Top Dividend Stocks to Buy Now and Hold For a DecadeNov 30, 2025 •By William DahlThis 7% Yielder Could Be a Top AI Play